Related Experiment Video
Updated: Feb 6, 2026
Determining the Reactivity and Titre of Serum using a Haemagglutination Assay
Published on: January 29, 2010
C-Reactive Protein to Serum Albumin Ratio Is an Independent Predictor of All-Cause Mortality in Patients with
Jae Seung Moon1, Sung Soo Ahn1, Yong Beom Park2,3
1Department of Biotechnology, Yonsei University College of Life Science and Biotechnology, Seoul, Korea.
Insights
The C-reactive protein (CRP) to serum albumin ratio (CAR) can predict mortality in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Higher CAR levels indicate increased risk, similar to diabetes mellitus.
Area of Science:
- Rheumatology
- Internal Medicine
- Clinical Biomarkers
Background:
- Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of systemic autoimmune diseases.
- Identifying reliable predictors of all-cause mortality in AAV patients is crucial for risk stratification and management.
- The C-reactive protein (CRP) to serum albumin ratio (CAR) is a potential inflammatory marker.
Purpose of the Study:
- To determine if the CAR is an independent predictor of all-cause mortality in patients diagnosed with AAV.
- To compare the predictive value of CAR with established risk factors like diabetes mellitus (DM).
Main Methods:
- Retrospective review of medical records for 170 AAV patients.
- Collection of clinical and laboratory data, including CRP and serum albumin levels at diagnosis.
- Univariable and multivariable Cox hazard model analyses to assess mortality predictors.
Main Results:
- The mean CAR at diagnosis was 14.8. Fourteen patients (8.2%) died during a mean follow-up of 56.7 months.
- CAR at diagnosis was identified as an independent predictor of all-cause mortality.
- Patients with CAR ≥10.35 and diabetes mellitus had a higher mortality frequency.
Conclusions:
- The CAR at diagnosis is a significant independent predictor of all-cause mortality in AAV patients.
- CAR's predictive capability is comparable to that of diabetes mellitus, a known mortality risk factor.
- CAR offers a valuable tool for assessing prognosis in AAV.
Purpose:
We investigated whether C-reactive protein (CRP) to serum albumin ratio (CAR) could be an independent predictor of all-cause mortality in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Materials And Methods:
We retrospectively reviewed the medical records of 170 patients with AAV. We collected clinical and laboratory data. We also examined AAV-related and traditional risk factors of all-cause mortality. To assess the hazard ratios of variables, we performed univariable and multivariable Cox hazard model analyses.
Results:
The mean age was 55.0 years and 53 patients (31.2%) were male among 170 patients with AAV (88 microscopic polyangiitis, 43 granulomatosis with polyangiitis, and 39 eosinophilic granulomatosis with polyangiitis). ANCA was detected in 129 patients (75.9%). The initial mean CRP and serum albumin were 41.1 (mg/L) and 3.6 (g/dL), and the mean CAR at diagnosis was 14.8. The most common risk factor of mortality was hypertension (42.4%), followed by chronic kidney disease ≥stage 3 (25.9%). Fourteen patients (8.2%) died during the mean follow-up of 56.7 months. In both multivariable Cox hazard model analyses, CAR at diagnosis was identified as an independent predictor of all-cause of mortality comparable to diabetes mellitus (DM). Moreover, patients with CAR ≥10.35 and having DM exhibited a higher frequency of all-cause mortality than those without.
Conclusion:
CAR at diagnosis can be an independent predictor of all-cause mortality, comparable to DM, the conventional risk factor of mortality.
More Related Videos
Related Concept Videos
01:21Introduction to Test of Independence
The test statistic for a test of independence is similar to that of a goodness-of-fit test:
01:16Hypothesis Test for Test of Independence
H0: The two variables (factors)...
02:03Law of Independent Assortment
01:23Poisson's Ratio
01:09Odds Ratio
01:12Hazard Ratio
For example, in a clinical trial...